PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.
| Revenue (Most Recent Fiscal Year) | $1.96M |
| Net Income (Most Recent Fiscal Year) | $-3.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.46 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -166.58% |
| Net Margin (Trailing 12 Months) | -166.58% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -383.19% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 11.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.04 |
| Exchange | NASDAQ |
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| Common Shares Outstanding | 111.89M |
| Free Float | 63.17M |
| Market Capitalization | $10.16M |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 0.39 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 43.54% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |